Initial therapy of patients with Wilson's disease with tetrathiomolybdate

G. J. Brewer, R. D. Dick, V. Yuzbasiyan-Gurkin, R. Tankanow, A. B. Young and K. J. Kluin
Department of Human Genetics, University of Michigan, Ann Arbor 48109-0618.

Patients with Wilson's disease who present with acute neurological symptoms often become clinically worse when initially treated with penicillamine. Other available anticopper drug therapies do not appear to offer a solution to this treatment problem. We are developing and evaluating a new drug, ammonium tetrathiomolybdate for this purpose. Theoretically, tetrathiomolybdate has optimal properties, including an immediate blockade of copper absorption and the property of forming complexes with copper in the blood, rendering the copper nontoxic. In this article, we present results from six patients treated with tetrathiomolybdate for up to 8 weeks as initial therapy. None of the five patients who had presented with acute neurological symptoms worsened. Also presented are methods of assay, preliminary stability studies, and methods of evaluating therapeutic end points with respect to copper metabolism.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tetrathiomolybdate Is Partially Protective Against Hyperglycemia in Rodent Models of Diabetes
Zeng et al.
Exp. Biol. Med. 2008;233:1021-1025.
ABSTRACT | FULL TEXT  

Tetrathiomolybdate Protects against Bile Duct Ligation-Induced Cholestatic Liver Injury and Fibrosis
Song et al.
J. Pharmacol. Exp. Ther. 2008;325:409-416.
ABSTRACT | FULL TEXT  

Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes
de Bie et al.
J. Med. Genet. 2007;44:673-688.
ABSTRACT | FULL TEXT  

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate: IV. Comparison of Tetrathiomolybdate and Trientine in a Double-blind Study of Treatment of the Neurologic Presentation of Wilson Disease.
Brewer et al.
Arch Neurol 2006;63:521-527.
ABSTRACT | FULL TEXT  

The Effect of Tetrathiomolybdate on Cytokine Expression, Angiogenesis, and Tumor Growth in Squamous Cell Carcinoma of the Head and Neck
Teknos et al.
Arch Otolaryngol Head Neck Surg 2005;131:204-211.
ABSTRACT | FULL TEXT  

Effects of Tetrathiomolybdate in a Mouse Model of Retinal Neovascularization
Elner et al.
IOVS 2005;46:299-303.
ABSTRACT | FULL TEXT  

Tetrathiomolybdate Therapy Protects Against Concanavalin A and Carbon Tetrachloride Hepatic Damage in Mice
Askari et al.
Exp. Biol. Med. 2004;229:857-863.
ABSTRACT | FULL TEXT  

Inhibition of the Growth of Squamous Cell Carcinoma by Tetrathiomolybdate-Induced Copper Suppression in a Murine Model
Cox et al.
Arch Otolaryngol Head Neck Surg 2003;129:781-785.
ABSTRACT | FULL TEXT  

Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer
Redman et al.
Clin. Cancer Res. 2003;9:1666-1672.
ABSTRACT | FULL TEXT  

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate: III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy
Brewer et al.
Arch Neurol 2003;60:379-385.
ABSTRACT | FULL TEXT  

Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis
Pan et al.
Cancer Res. 2002;62:4854-4859.
ABSTRACT | FULL TEXT  

Copper Control as an Antiangiogenic Anticancer Therapy: Lessons from Treating Wilson's Disease
Brewer
Exp. Biol. Med. 2001;226:665-673.
ABSTRACT | FULL TEXT  

Recognition, Diagnosis, and Management of Wilson's Disease
Brewer
Exp. Biol. Med. 2000;223:39-46.
ABSTRACT | FULL TEXT  

Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenic Agent: Phase I Study
Brewer et al.
Clin. Cancer Res. 2000;6:1-10.
ABSTRACT | FULL TEXT  

Molybdenum: An Essential Trace Element
Sardesai
Nutr Clin Pract 1993;8:277-281.
ABSTRACT